Free Trial
NASDAQ:VCEL

Vericel (VCEL) Stock Price, News & Analysis

Vericel logo
$39.93 -1.30 (-3.15%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$39.92 -0.01 (-0.01%)
As of 07/11/2025 05:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Vericel Stock (NASDAQ:VCEL)

Key Stats

Today's Range
$39.74
$40.88
50-Day Range
$38.45
$45.70
52-Week Range
$37.39
$63.00
Volume
309,779 shs
Average Volume
421,282 shs
Market Capitalization
$2.01 billion
P/E Ratio
1,331.44
Dividend Yield
N/A
Price Target
$61.14
Consensus Rating
Buy

Company Overview

Vericel Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
74th Percentile Overall Score

VCEL MarketRank™: 

Vericel scored higher than 74% of companies evaluated by MarketBeat, and ranked 264th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Vericel has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Vericel has only been the subject of 1 research reports in the past 90 days.

  • Read more about Vericel's stock forecast and price target.
  • Earnings Growth

    Earnings for Vericel are expected to grow by 214.29% in the coming year, from $0.14 to $0.44 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Vericel is 1,331.44, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.84.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Vericel is 1,331.44, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.13.

  • Price to Book Value per Share Ratio

    Vericel has a P/B Ratio of 6.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Vericel's valuation and earnings.
  • Percentage of Shares Shorted

    4.89% of the float of Vericel has been sold short.
  • Short Interest Ratio / Days to Cover

    Vericel has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vericel has recently decreased by 71.77%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Vericel does not currently pay a dividend.

  • Dividend Growth

    Vericel does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.89% of the float of Vericel has been sold short.
  • Short Interest Ratio / Days to Cover

    Vericel has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vericel has recently decreased by 71.77%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Vericel has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.00 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Vericel this week, compared to 6 articles on an average week.
  • Search Interest

    3 people have searched for VCEL on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Vericel to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Vericel insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.20% of the stock of Vericel is held by insiders.

  • Read more about Vericel's insider trading history.
Receive VCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter.

VCEL Stock News Headlines

A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
Vericel Corporation: Moving From Sell To Neutral
See More Headlines

VCEL Stock Analysis - Frequently Asked Questions

Vericel's stock was trading at $54.91 at the beginning of 2025. Since then, VCEL stock has decreased by 27.3% and is now trading at $39.93.

Vericel Corporation (NASDAQ:VCEL) announced its quarterly earnings data on Thursday, May, 8th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.14. The company's revenue for the quarter was up 2.6% compared to the same quarter last year.
Read the conference call transcript
.

Vericel's top institutional shareholders include Diversified Trust Co (0.02%) and Juncture Wealth Strategies LLC (0.01%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Paul K Wotton, Robert L Md Zerbe, Joseph Anthony Mara Jr, Steven C Gilman, Jonathan Siegal, Michael Halpin and Sean C Flynn.
View institutional ownership trends
.

Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vericel investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Palo Alto Networks (PANW) and Netflix (NFLX).

Company Calendar

Last Earnings
5/08/2025
Today
7/12/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VCEL
CIK
887359
Employees
300
Year Founded
1989

Price Target and Rating

High Price Target
$67.00
Low Price Target
$51.00
Potential Upside/Downside
+53.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.03
Trailing P/E Ratio
1,331.44
Forward P/E Ratio
285.21
P/E Growth
N/A
Net Income
$10.36 million
Net Margins
1.25%
Pretax Margin
1.31%
Return on Equity
1.09%
Return on Assets
0.73%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.01
Quick Ratio
4.58

Sales & Book Value

Annual Sales
$237.22 million
Price / Sales
8.47
Cash Flow
$0.30 per share
Price / Cash Flow
131.94
Book Value
$5.92 per share
Price / Book
6.74

Miscellaneous

Outstanding Shares
50,340,000
Free Float
47,725,000
Market Cap
$2.01 billion
Optionable
Optionable
Beta
1.32

Social Links

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:VCEL) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners